Single Dose of Recombinant VSV-ΔG-Spike Vaccine Protects Against SARS-CoV-2
The COVID-19 pandemic sparked the need to develop an efficient and cost-effective vaccine to provide mass immunization against SARS-CoV-2, the virus that causes COVID-19. An Israeli study, initially published in June 2020 on the preprint server bioRxiv, examined the possibility of generating a new recombinant vaccine to protect against SARS-CoV-2. The report is now available